Boule Diagnostics has contracted Diakon ZAO as the distributor of Swelab-systems on the Russian market. Russia is a large and rapidly growing market for complete blood cell count and with Diakon, a supplement to existing distributors, Boule is well positioned to continue to take market share in Russia.
Ernst Westman, President CEO of Boule Diagnostics AB, comments;
“Russia is one of our most important markets where we for a long time have had a very good cooperation with Unimed for the sales of the Medonic-system. We are now adding Diakon for the sale of our Swelab-systems. Diakon has a very broad geographic coverage of the Russian market and a product portfolio that complements Boule’s offer. We expect to see an increase of sold instruments this year on the Russian market, and thereby continued increase in the sales of consumables, which in time will generat higher margins.”
Diakon ZAO is one of Russia’s largest companies within in vitro diagnostics (IVD) with sales in more than 60 major cities all across Russia.
For more information, please contact:
Ernst Westman, President CEO Boule Diagnostics AB, phone 0708-60 88 63
The information disclosed in this press release is such that Boule Diagnostics AB is required to make this information public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for publication on August 16, 2012 at 08.00 am (CET).
TO THE EDITORS
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. http://www.boule.se